Aravive, Inc. Stock
Price
Target price
-
-
-
-
-
?16.19
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Aravive, Inc. Stock
With 0 Sell predictions and 1 Buy predictions the community sentiment towards the Aravive, Inc. stock is not clear.
Based on the current price of 0.03 € the target price of 16 € shows a potential of 49130.77% for Aravive, Inc. which would more than double the current price.
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Aravive, Inc. stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of Aravive, Inc. in the next few years
Pros
?
B****
?
S********** s********
?
W********* I********* f** t** n*** y****
Cons
?
M***** P*******
?
C******** o* t** e**********
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Aravive, Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Aravive, Inc. | - | - | - | - | - | - | - |
| Ardelyx Inc. | -3.190% | -5.210% | -13.459% | 49.277% | 10.796% | -11.669% | - |
| Salarius Pharmaceuticals Inc. | 5.880% | -0.971% | -34.720% | -69.778% | -26.486% | -98.400% | -99.995% |
| Evolus Inc | -2.630% | -8.197% | -12.500% | 43.590% | 19.786% | 18.519% | - |
Comments
Aravive, Inc. (NASDAQ: ARAV) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $18.00 price target on the stock.
Show more
Ratings data for ARAV provided by MarketBeat
